Literature DB >> 15968111

Methylation-specific polymerase chain reaction.

Oliver Galm1, James G Herman.   

Abstract

Methylation-specific polymerase chain reaction (MSP) is a method that can rapidly assess the methylation status of virtually any group of CpG sites within a CpG island, independent of the use of methylation-sensitive restriction enzymes. This assay entails the initial modification of DNA by sodium bisulfite, converting all unmethylated cytosines to uracils but leaving the methylated cytosines unchanged, followed by subsequent amplification with primers specific for methylated vs unmethylated DNA. The great sensitivity of this technique allows qualitative methylation analysis from DNA obtained not only from fresh frozen tissues, peripheral blood, bone marrow, or body fluids but also from paraffin-embedded samples. It is a rapid and cost-effective method that does not require radioactive reagents and can be used for the analysis of a large number of clinical samples.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968111     DOI: 10.1385/1-59259-916-8:279

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  14 in total

1.  A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR.

Authors:  Rainer Claus; Stefan Wilop; Thomas Hielscher; Miriam Sonnet; Edgar Dahl; Oliver Galm; Edgar Jost; Christoph Plass
Journal:  Epigenetics       Date:  2012-07-01       Impact factor: 4.528

Review 2.  [Methylation and other new concepts for the origin of hepatocellular carcinoma].

Authors:  A Tannapfel
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

3.  Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder.

Authors:  Hamid Mostafavi Abdolmaleky; Kuang-Hung Cheng; Stephen V Faraone; Marsha Wilcox; Stephen J Glatt; Fangming Gao; Cassandra L Smith; Rahim Shafa; Batol Aeali; Julie Carnevale; Hongjie Pan; Panagiotis Papageorgis; Jose F Ponte; Vadivelu Sivaraman; Ming T Tsuang; Sam Thiagalingam
Journal:  Hum Mol Genet       Date:  2006-09-19       Impact factor: 6.150

4.  [Novel prognostic marker in invasive breast cancer. ITIH5 expression is abrogated by aberrant promoter methylation].

Authors:  J Veeck; E Breuer; M Rose; M Chorovicer; A Naami; N Bektas; S Alkaya; S von Serényi; F Horn; A Hartmann; R Knüchel; E Dahl
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

5.  Aberrant Methylation of Tumour Suppressor Gene ADAM12 in Chronic Lympocytic Leukemia Patients: Application of Methylation Specific-PCR Technique.

Authors:  Amira Mohamad; Rosline Hassan; Azlan Husin; Muhammad Farid Johan; Sarina Sulong
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01

6.  Development of a quantitative methylation-specific polymerase chain reaction method for monitoring beta cell death in type 1 diabetes.

Authors:  Mohamed I Husseiny; Akio Kuroda; Alexander N Kaye; Indu Nair; Fouad Kandeel; Kevin Ferreri
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

7.  Adenoviral delivery of the EMX2 gene suppresses growth in human gastric cancer.

Authors:  Jie Li; Minli Mo; Zhao Chen; Zhe Chen; Qing Sheng; Hang Mu; Fang Zhang; Yi Zhang; Xiu-Yi Zhi; Hui Li; Biao He; Hai-Meng Zhou
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

8.  Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer.

Authors:  Jason P W Carey; Ananthi J Asirvatham; Oliver Galm; Tandeih A Ghogomu; Jaideep Chaudhary
Journal:  BMC Cancer       Date:  2009-06-07       Impact factor: 4.430

9.  Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening.

Authors:  Vera Kloten; Birte Becker; Kirsten Winner; Michael G Schrauder; Peter A Fasching; Tobias Anzeneder; Jürgen Veeck; Arndt Hartmann; Ruth Knüchel; Edgar Dahl
Journal:  Breast Cancer Res       Date:  2013-01-15       Impact factor: 6.466

10.  Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.

Authors:  Jürgen Veeck; Erik Noetzel; Nuran Bektas; Edgar Jost; Arndt Hartmann; Ruth Knüchel; Edgar Dahl
Journal:  Mol Cancer       Date:  2008-11-06       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.